Journal of Korean Traditional Oncology (대한암한의학회지)

Korean Association of Traditional Oncology (대한암한의학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of Hormone Receptor Positive and HER-2 Receptor Positive Metastatic Breast Cancer Stage IV Patient Treated with a Combination of Traditional Korean Medicine and Chemotherapy for 6 Years

호르몬 수용체 및 HER-2 수용체 양성 유방암 4기 다발성 전이 환자의 6년간의 한양방 병용치료 치험 1례

  • Received : 2019.11.27
  • Accepted : 2019.12.22
  • Published : 2019.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : The purpose of this study is to report and observe effects of Traditional Korean Medicine (TKM) on stage IV metastatic breast cancer patient. Method : A right breast cancer patient diagnosed with metastatic lesions on liver, lung, spleen, multiple bones and skin on right breast April 2013. The patient received Herceptin + Docetaxel + Zometa from May 2013 and started to receive TKM since July 2013 to decrease side effects of chemotherapy. From December 2013 to November 2014, she had received Herceptin 18 times more. The clinical outcomes were measured by computed tomography, laboratory findings including tumor markers (CEA, CA15-3), liver function test (AST, ALT), and numeric rating scales (NRS). Results : After 6 years of TKM treatment combined with standard chemotherapy, tumor size was partially decreased in lung, liver, right pleura and spleen. Levels of tumor markers also showed decrease. There were no severe adverse events induced by TKM based on National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE) version 4.0. Conclusion : This case suggests that TKM combined with standard chemotherapy could be a promising method for treating metastatic stage IV breast cancer.

Keywords

References

  1. Akram, M., Iqbal, M., Daniyal, M. et al. Awareness and current knowledge of breast cancer. Biol Res. 50:1-23, 2017 https://doi.org/10.1186/s40659-016-0106-3
  2. 국가암정보센터 [cited 2019 Nov 14] Available from:URL: https://www.cancer.go.kr/lay1/program/S1T211C217/cancer/view.do?cancer_seq=4757&menu_seq=4762
  3. 윤미란, 류지영, 송병주, 채병주, 유태경. 호르몬 수용체 약양성 유방암과 삼중음 성 유방암의 치료 예후. 한국유방암학회. 7:1-8, 2019 https://doi.org/10.4048/jkbcs.2004.7.1.1
  4. Santa-Maria CA, Nye L, Mutonga MB, Jain S, Gradishar WJ. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do WeGo From Here? Oncology (Williston Park). 30:148-155, 2016
  5. 한가진, 이아람, 성신, 김성수. 진행성 유방암에 대한 한양방 병용 치료 치험 1례. 대한한방내과학회지. 9:268-276, 2018
  6. 한가진, 이아람, 정준석, 성신, 김성수. 유방암에 대한 한양방 병용 치료 증례 보고 1례. 대한한방내과학회지. 38:820-827, 2017 https://doi.org/10.22246/jikm.2017.38.5.820
  7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. New response evaluation criteria in solid tumours: Revised RECIST guideline(version 1.1). Eur J Cancer 45:228-247, 2009 https://doi.org/10.1016/j.ejca.2008.10.026
  8. Karcioglu O, Topacoglu H, Dikme O (2018) A systematic review of the pain scales in adults: Which to use? Am J Emerg Med. 36:707-714, 2018 https://doi.org/10.1016/j.ajem.2018.01.008
  9. National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE) v.4.0, 2010. [cited 2019 Nov 10] Available from:URL: http://evs.nci.nih.gov/ftp1/CTCAE/About.html)
  10. Guo YH, Kuruganti R, Gao Y. Recent Advances in Ginsenosides as Potential Therapeutics Against Breast Cancer. Curr Top Med Chem. 1:1-5, 2019. https://doi.org/10.2174/1568026013395560
  11. 전국한의과대학 본초학교수 공편저. 본초학. p. 531, 서울, 영림사, 1994
  12. 중약대사전편찬위원회. 완역중약대사전. 권7. p. 3473-3479, 서울, 정담, 1997
  13. Nakhjavani, M., Hardingham, J.E., Palethorpe, H.M., Tomita, Y., Smith, E., Price, T.J., et al. Ginsenoside rg3: Potential molecular targets and therapeutic indication in metastatic breast cancer. Medicines. 6:17-37, 2019 https://doi.org/10.3390/medicines6010017
  14. Lee, H., Lee, S., Jeong, D. & Kim, S. J. Ginsenoside Rh2 epigenetically regulates cell-mediated immune pathway to inhibit proliferation of MCF-7 breast cancer cells. J. Ginseng Res. 42:455-462, 2018 https://doi.org/10.1016/j.jgr.2017.05.003
  15. Zhu J, Zhang H, Zhu Z, et al. Effects and mechanism of flavonoids from Astragalus complanatus on breast cancer growth. Naunyn Schmiedebergs Arch Pharmacol. 388:965-972, 2015 https://doi.org/10.1007/s00210-015-1127-0
  16. Li W, Song K, Wang S, et al. Anti-tumor potential of astragalus polysaccharides on breast cancer cell line mediated by macrophage activation. Mater Sci Eng C Mater Biol Appl. 98:685-695, 2019 https://doi.org/10.1016/j.msec.2019.01.025
  17. Zhou R, Chen H, Chen J, Chen X, Wen Y, Xu L. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC Complement Altern Med. 18:83, 2018 https://doi.org/10.1186/s12906-018-2148-2
  18. Madden, R., Kosari, S., Peterson, G.M., Bagheri, N., Thomas, J. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review. Int. J. Clin. Pharmacol. Ther. 56:72-80, 2018 https://doi.org/10.5414/cp203123
  19. Martin Huertas, R., Fernandez Abad, M., Corral de la Fuente, E., et al. Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response. Breast J. 2:5-9, 2019
  20. Dieras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER 2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18:732-742, 2017 https://doi.org/10.1016/S1470-2045(17)30312-1